Mannose receptor Inhibitors
1 drugsAbout Mannose receptor
The Mannose Receptor (MR), or CD206, is a C-type lectin receptor on macrophages and dendritic cells. It binds mannose and other carbohydrates on pathogens, triggering phagocytosis and immune responses.
The Mannose Receptor is a therapeutic target due to its role in innate immunity. There is currently no genetic evidence directly linking the Mannose Receptor to specific diseases.
One FDA-approved drug, ELELYSO (Pfizer), targets the Mannose Receptor for rare disease indications. It is a biologic (other) modality, approved in 2012.
Top Mannose receptor Drugs
Pfizer is the only company with an approved drug targeting the Mannose Receptor.
Low competition suggests a potential first-mover advantage, but also indicates higher market entry barriers.
Mannose receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Mannose receptor, using enzyme modality.
The absence of small molecule or antibody drugs represents a whitespace opportunity for novel modalities.
Mannose receptor Clinical Trials 7 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Mannose receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Mannose receptor Drug Approval Timeline (2012 - 2012)
The first and only drug was approved in 2012.
The approval timeline suggests market saturation; new entrants require differentiated mechanisms or indications.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 2 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Mannose receptor. A trial counts if an approved drug acting on Mannose receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.